Dr. Euryclides Hospital de Jesus Zerbini

The fields where it stands highest, over all time, ranked among every institution above the floor in each field.

Each strip is that field’s whole ranked pool, with the notch where Dr. Euryclides Hospital de Jesus Zerbini sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).

Where its research is concentrated relative to its size: Medicine takes 3.7× the share of its output that it takes of world research.

1. MedicineField · 52.4 works3.7×

Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

• Medicine 3.7×
• Veterinary 3.4×
• Immunology and Microbiology 2.1×
• Health Professions 1.5×
• Biochemistry, Genetics and Molecular Biology 1.2×
• Dentistry 1.2×
• Decision Sciences 0.9×
• Pharmacology, Toxicology and Pharmaceutics 0.9×
• Economics, Econometrics and Finance 0.5×
• Social Sciences 0.4×
• Neuroscience 0.4×
• Environmental Science 0.3×
• Agricultural and Biological Sciences 0.2×
• Computer Science 0.2×
• Business, Management and Accounting 0.2×
• Engineering 0.1×
• Physics and Astronomy 0.1×
• Psychology 0.1×

Ranked on the composite score, Bernardo Liberman, Arthur Cukiert and LLM Perobelli lead among researchers whose main affiliation is Dr. Euryclides Hospital de Jesus Zerbini.

1. 1 🇧🇷 Bernardo Liberman Brazil · #577,542 worldwide 46 citations · 25 works
2. 2 🇧🇷 Arthur Cukiert Brazil · #738,160 worldwide 52 citations · 30 works
3. 3 🇧🇷 LLM Perobelli Brazil · #1,524,628 worldwide 1 citations · 16 works

By fractional works in 2022–2025, weighted toward what it does more of than the world: Prognostic Factors, Hematopoietic Stem Cells, Acute Myeloid Leukemia, AML, Rituximab, Chronic Lymphocytic Leukemia, Genomic Aberrations and Mutation.

By volume in 2022–2025: Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research and Acute Lymphoblastic Leukemia research.

1. 1 Acute Myeloid Leukemia Research Hematology 8 works
2. 2 Chronic Myeloid Leukemia Treatments Hematology 5 works
3. 3 Chronic Lymphocytic Leukemia Research Genetics 5 works
4. 4 Acute Lymphoblastic Leukemia research Public Health, Environmental and Occupational Health 3 works
5. 5 Cutaneous lymphoproliferative disorders research Dermatology 2 works
6. 6 Renal and related cancers Molecular Biology 2 works
7. 7 Kidney Stones and Urolithiasis Treatments Pulmonary and Respiratory Medicine 2 works
8. 8 Rural and Ethnic Education Education 1 works
9. 9 Myeloproliferative Neoplasms: Diagnosis and Treatment Genetics 1 works
10. 10 Retinoids in leukemia and cellular processes Molecular Biology 1 works

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

Output in 2018–2022 was 135% higher than in 2013–2017.

• Universidade de São Paulo
• Universidade Estadual Paulista (Unesp)
• Universidade Federal de São Paulo
• Pontifícia Universidade Católica de São Paulo
• Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
• Hospital Universitário da Universidade de São Paulo
• Universidade Brasil
• Universidade Presbiteriana Mackenzie